Our mission is to revolutionise the treatment of cancer and fibrotic diseases through precision delivery of therapeutic siRNAs, using our proprietary gene delivery technology, LipTide

NanoGenics is a leading siRNA therapeutics company looking to address major unmet need in oncology and ophthalmology. Our lead product, ECP-102, enhances chemotherapy by sensitising cancer cells to cell death. It will be in the clinic in 2021, followed closely by several other promising medicines in rapid development now. This includes our novel glaucoma therapy, ECP-105, as well as several other therapies ranging across a number of disease areas.

The precision delivery of our products is accomplished by harnessing our unique proprietary delivery technology, LipTide.

Please contact us to learn more about how we are taking our products all the way to the clinic door.